Dyne Therapeutics 과거 순이익 실적

과거 기준 점검 0/6

Dyne Therapeutics의 수입은 연평균 -30.9%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 30% 증가했습니다.

핵심 정보

-30.95%

순이익 성장률

-3.81%

주당순이익(EPS) 성장률

Biotechs 산업 성장률	17.04%
매출 성장률	n/a
자기자본이익률	-45.90%
순이익률	n/a
최근 순이익 업데이트	31 Dec 2025

최근 과거 실적 업데이트

업데이트 없음

Recent updates

Dyne Therapeutics: Why The $350M Public Offering Was Critical

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

Jun 17

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 13

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Feb 28

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

매출 및 비용 세부 내역

Dyne Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGS:DYN 매출, 비용 및 순이익 (USD Millions)
날짜	순이익	일반관리비	연구개발비
31 Dec 25	-446	70	398
30 Sep 25	-424	64	385
30 Jun 25	-413	61	380
31 Mar 25	-367	54	343
31 Dec 24	-317	62	281
30 Sep 24	-295	56	258
30 Jun 24	-258	50	221
31 Mar 24	-257	48	218
31 Dec 23	-236	31	211
30 Sep 23	-208	30	185
30 Jun 23	-189	30	165
31 Mar 23	-177	29	152
31 Dec 22	-168	28	143
30 Sep 22	-181	31	152
30 Jun 22	-182	30	154
31 Mar 22	-160	30	131
31 Dec 21	-149	29	121
30 Sep 21	-126	26	101
30 Jun 21	-97	23	74
31 Mar 21	-77	18	58
31 Dec 20	-59	13	45
30 Sep 20	-36	8	27
30 Jun 20	-28	5	21
31 Mar 20	-21	4	15
31 Dec 19	-15	3	11

양질의 수익: DYN 은(는) 현재 수익성이 없습니다.

이익 마진 증가: DYN는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: DYN은 수익성이 없으며 지난 5년 동안 손실이 연평균 30.9% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 DYN의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: DYN은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(40.2%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: DYN는 현재 수익성이 없으므로 자본 수익률이 음수(-45.9%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/04 22:37
종가	2026/05/04 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Dyne Therapeutics, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Brian Skorney	Baird
William Pickering	Bernstein
Keay Nakae	Chardan Capital Markets, LLC

Dyne Therapeutics 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

Recent updates

Dyne Therapeutics Announces to Present New Preclinical Data Demonstrating the Ability of the Force Platform to Cross the Blood-Brain Barrier

Dyne Therapeutics, Inc., Annual General Meeting, Jun 05, 2026

Dyne Therapeutics, Inc. Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z Rostudirsen in Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc. Announces the Appointment of Vikram Karnani to Its Board of Directors

Price target increased by 10% to US$39.00

Dyne Therapeutics: Why The $350M Public Offering Was Critical

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $350.000014 million.

Dyne Therapeutics, Inc. Announces Topline Results from Registrational Expansion Cohort of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc. Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Insufficient new directors

Dyne Therapeutics, Inc. Appoints Brian Posner to Its Board of Directors

Dyne Therapeutics, Inc. Announces Fda Breakthrough Therapy Designation for Dyne-251 in Duchenne Muscular Dystrophy (Dmd)

Price target decreased by 8.3% to US$36.32

CEO, President & Director recently bought US$911k worth of stock

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000006 million.

Price target decreased by 8.4% to US$40.35

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

Dyne Therapeutics, Inc., Annual General Meeting, May 30, 2025

Dyne Therapeutics, Inc. Announces New Long-Term Clinical Data from Phase 1/2 Deliver Trial of Dyne-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

New major risk - Shareholder dilution

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics to Present Data from the Ongoing DELIVER Clinical Trial in Duchenne Muscular Dystrophy At Upcoming Presentations At the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics: Moving Forward On 2 Key Fronts

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

New minor risk - Share price stability

Dyne Therapeutics, Inc. Announces New Clinical Data from Its Ongoing Phase 1/2 Achieve Trial of Dyne-10 in Patients with Myotonic Dystrophy Type 1 (DM1)

New minor risk - Insider selling

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50